JAK2 in Myeloproliferative Neoplasms: Still a Protagonist
The discovery of the activating V617F mutation in Janus kinase 2 (JAK2) has been decisive for the understanding of myeloproliferative neoplasms (MPN). Activated JAK2 signaling by <i>JAK2</i>, <i>CALR,</i> and <i>MPL</i> mutations has become a focus for the develop...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-01-01
|
| Series: | Pharmaceuticals |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1424-8247/15/2/160 |